Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Oligometastatic Disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Oligometastatic Disease. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Oligometastatic Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 3: 1.

Research is led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1), MedSIR (1), Peking University First Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is MR-linac (device, 1 trial), followed by Niraparib oral tablets, Systematic therapy combined with radiotherapy.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
1
Phase 3 Trials
4
Sponsors

Track Oligometastatic Disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05183074

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)

1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer 2. To assess the acute and late...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 501 location
RECRUITINGPhase 2NCT06180356

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery...

Sponsor: MedSIREnrolling: 3014 locations
RECRUITINGNCT06652022

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs

This study was a prospective, open-label, phase II randomised controlled clinical study, enrolling patients with primary oligometastatic uroepithelial carcinoma, oligometastasis...

Sponsor: Peking University First HospitalEnrolling: 1022 locations
RECRUITINGPhase 3NCT06190782

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1...

Sponsor: Fudan UniversityEnrolling: 3541 location

Frequently Asked Questions

There are currently 4 clinical trials for Oligometastatic Disease, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Oligometastatic Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Oligometastatic Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.